This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MLND vs. SBTX, UPB, SION, PRTA, KURA, COGT, AKBA, STOK, GHRS, and TYRAShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include Silverback Therapeutics (SBTX), Upstream Bio (UPB), Sionna Therapeutics (SION), Prothena (PRTA), Kura Oncology (KURA), Cogent Biosciences (COGT), Akebia Therapeutics (AKBA), Stoke Therapeutics (STOK), GH Research (GHRS), and Tyra Biosciences (TYRA). These companies are all part of the "medical" sector. Millendo Therapeutics vs. Silverback Therapeutics Upstream Bio Sionna Therapeutics Prothena Kura Oncology Cogent Biosciences Akebia Therapeutics Stoke Therapeutics GH Research Tyra Biosciences Silverback Therapeutics (NASDAQ:SBTX) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations. Does the media prefer SBTX or MLND? In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Millendo Therapeutics'average media sentiment score. Company Overall Sentiment Silverback Therapeutics Neutral Millendo Therapeutics Neutral Does the MarketBeat Community believe in SBTX or MLND? Silverback Therapeutics received 18 more outperform votes than Millendo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformSilverback TherapeuticsOutperform Votes1856.25% Underperform Votes1443.75% Millendo TherapeuticsN/AN/A Is SBTX or MLND more profitable? Silverback Therapeutics' return on equity of -29.62% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silverback TherapeuticsN/A -29.62% -28.20% Millendo Therapeutics N/A -91.03%-72.44% Do insiders & institutionals believe in SBTX or MLND? 74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, SBTX or MLND? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilverback TherapeuticsN/AN/A-$89.48M-$2.42-5.98Millendo TherapeuticsN/AN/A-$36.41MN/AN/A Which has more volatility and risk, SBTX or MLND? Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. SummarySilverback Therapeutics beats Millendo Therapeutics on 6 of the 7 factors compared between the two stocks. Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$133.11M$6.85B$5.55B$8.02BDividend YieldN/A2.97%5.09%4.23%P/E RatioN/A7.4422.6918.83Price / SalesN/A257.59404.29106.72Price / CashN/A65.8538.1834.62Price / Book3.936.576.794.33Net Income-$36.41M$143.14M$3.22B$247.97M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$6.99+2.0%N/A+93.5%$133.11MN/A0.0012SBTXSilverback TherapeuticsN/A$14.88flatN/A+49.7%$536.54MN/A-6.1583Gap UpHigh Trading VolumeUPBUpstream BioN/A$9.90+2.0%$56.50+470.7%N/A$525.84M$2.37M0.0038News CoveragePositive NewsSIONSionna TherapeuticsN/A$11.66+3.2%$38.50+230.2%N/A$514.49MN/A0.0035Gap DownPRTAProthena3.6944 of 5 stars$9.52+2.4%$55.00+477.8%-61.4%$512.43M$135.16M-4.14130Upcoming EarningsInsider TradeNews CoveragePositive NewsKURAKura Oncology4.1126 of 5 stars$6.19+0.2%$25.50+312.0%-68.6%$502.04M$53.88M-2.63130Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsCOGTCogent Biosciences2.191 of 5 stars$4.37+1.6%$14.43+230.2%-19.5%$498.66MN/A-1.7780Upcoming EarningsOptions VolumeAnalyst RevisionAKBAAkebia Therapeutics4.1037 of 5 stars$2.09+1.0%$6.50+211.0%+88.5%$494.90M$160.18M-9.11430Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoveragePositive NewsSTOKStoke Therapeutics3.4975 of 5 stars$9.14+6.1%$24.67+170.0%-17.6%$494.54M$36.56M-4.35100Upcoming EarningsGHRSGH Research1.7877 of 5 stars$9.32+1.6%$30.86+231.1%+1.8%$491.67MN/A-11.9610News CoverageTYRATyra Biosciences1.8603 of 5 stars$9.16+1.1%$30.83+236.5%-41.4%$486.36MN/A-5.6920Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies SBTX Alternatives UPB Alternatives SION Alternatives PRTA Alternatives KURA Alternatives COGT Alternatives AKBA Alternatives STOK Alternatives GHRS Alternatives TYRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLND) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLND Stock Free MLND Stock Alerts